From the Guidelines
In emphysema, pulmonary function tests typically show an obstructive pattern with specific characteristic changes, including a reduced FEV1/FVC ratio, decreased FEV1, increased Residual Volume (RV), and increased or normal Total Lung Capacity (TLC). The FEV1/FVC ratio is reduced, usually less than 0.7, indicating airflow limitation during forced expiration, as stated in the GOLD 2025 report 1. FEV1 is significantly decreased, often below 80% of predicted value, and worsens as the disease progresses. Residual Volume (RV) is markedly increased due to air trapping caused by the destruction of elastic tissue and early airway closure. Total Lung Capacity (TLC) is typically increased or normal, reflecting hyperinflation of the lungs. Additionally, you'll often see increased functional residual capacity (FRC) and decreased diffusing capacity for carbon monoxide (DLCO) due to destruction of the alveolar-capillary membrane.
These changes occur because emphysema destroys alveolar walls and reduces elastic recoil of the lungs, leading to air trapping during expiration and hyperinflation. The loss of alveolar surface area also impairs gas exchange, explaining the reduced diffusing capacity. The GOLD Science Committee recommends using the FEV1/FVC ratio to identify airflow obstruction, with a threshold value of less than 0.7 1. The use of pre- or post-bronchodilator spirometry for the diagnosis of COPD is also discussed, with the GOLD 2025 report recommending the use of post-bronchodilator measurements 1.
Some key points to consider when interpreting pulmonary function tests in emphysema include:
- The FEV1/FVC ratio is a key indicator of airflow limitation
- RV and TLC are often increased, reflecting air trapping and hyperinflation
- FRC and DLCO may also be affected, due to destruction of the alveolar-capillary membrane
- The GOLD Science Committee recommends using the FEV1/FVC ratio to identify airflow obstruction, with a threshold value of less than 0.7 1
- The use of pre- or post-bronchodilator spirometry for the diagnosis of COPD is also important, with the GOLD 2025 report recommending the use of post-bronchodilator measurements 1.
Overall, pulmonary function tests are an essential tool in the diagnosis and management of emphysema, and can help guide treatment decisions and monitor disease progression. The most recent and highest quality study, the GOLD 2025 report 1, provides guidance on the interpretation of pulmonary function tests in emphysema.
From the Research
Pulmonary Function Test Results in Emphysema
In a patient with emphysema, pulmonary function tests can reveal specific patterns that are characteristic of the disease. The following are key findings to expect:
- Forced Expiratory Volume (FEV1) to Forced Vital Capacity (FVC) ratio: A decreased FEV1/FVC ratio is indicative of airflow obstruction, which is a hallmark of emphysema 2. The ratio is calculated by dividing the FEV1 by the FVC, and a lower ratio suggests more severe airflow obstruction.
- Residual Volume (RV): Emphysema patients often have an increased RV due to air trapping, which is a result of the destruction of alveolar walls and the loss of elastic recoil in the lungs 3.
- Total Lung Capacity (TLC): TLC may be increased in emphysema patients due to hyperinflation of the lungs, which is a consequence of the air trapping and loss of elastic recoil 3.
Expected Findings
Based on the studies, the following findings can be expected in a patient with emphysema:
- A decreased FEV1/FVC ratio, indicating airflow obstruction 2
- An increased RV, indicating air trapping 3
- An increased TLC, indicating hyperinflation of the lungs 3
- A decreased FVC, which may be due to the loss of lung elastic recoil and the resulting hyperinflation 4
- A normal or decreased FEV1, which may be due to the airflow obstruction and the resulting decrease in lung function 5, 6
Variability in Response to Bronchodilators
The response to bronchodilators can vary depending on the severity of emphysema and the specific lung function parameters being measured. Some studies have shown that patients with more severe emphysema may have a greater response to bronchodilators in terms of volume parameters, such as IC and FVC, but a lesser response in terms of flow parameters, such as FEV1 6.